InfuSystems Holdings (INFU) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

InfuSystems Holdings

NYSE American•Healthcare•Medical Devices

$12.24+0.06(<0.01%)Market closed

Market Cap

$250.49M

P/E

29.3x

P/S

1.7x

P/B

4.2x

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

How this company scores

GoodMetricSide Score: 78/100

Strongest: Balance Sheet & Red Flags (22/25); weakest: Cash & Earnings Quality (18/25).

Profitability19/25

Growth19/25

Balance Sheet & Red Flags22/25

Cash & Earnings Quality18/25

Strengths

Rising earningsLow leverageInterest easily coveredCash-backed earnings

No red flags in the last 8 quarters.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 29.3x5y range 11.1x – 7251.5x

Currently below its 19-quarter median.

P/S · 1.7x5y range 0.8x – 1.7x

Currently above its 20-quarter median.

P/B · 4.2x5y range 2.1x – 4.2x

Price & Volume

Market Cap $250.49M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $143.34M
Q. Revenue: $36.93M
TTM EBITDA: $26.33M
TTM Op. Income: $13.27M
Q. Op. Income: $4.15M
TTM Net Income: $8.54M
Q. Net Income: $3.23M
EPS: $0.16
Shares Out.: $20.07M

$143.34M in TTM revenue grew 2.5% YoY, reaching $36.93M last quarter. TTM EBITDA of $26.33M and TTM operating income of $13.27M show growth is flowing through to the bottom line. TTM net income of $8.54M means revenue is converting into profit. Over the past year, TTM revenue is up 2% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 58.0%
EBITDA Margin: 19.8%
Op. Margin: 11.2%
Net Margin: 8.7%

Op. margin of 11.2% is up 0.8% YoY — cost efficiency is improving. Net margin at 8.7% and gross margin of 58.0% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 7% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 29.3x
P/S Ratio: 1.7x
P/B Ratio: 4.2x

At 29.3x P/E, the stock trades within typical market levels. P/S of 1.7x and P/B of 4.2x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 15% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $97.70M
Cash: $964,000
Long-Term Debt: $20.42M
Book Value: $59.15M
D/E Ratio: 0.3
Debt/EBITDA: 2.8

With $97.70M in assets and $20.42M in long-term debt, D/E is 0.3and book value is $59.15M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 29% — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $6.78M
TTM Free Cash Flow: $22.91M
FCF Margin: 16.0%
FCF / Net Income: 2.7

TTM FCF of $22.91M on $6.78M in operating cash flow. The FCF / Net Income ratio of 2.7x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.